MannKind
MNKD
3.45
-0.26
-7.01%
MannKind
US · MNKD
#3124 by market cap
Listed 2016
3.45
-0.26
-7.01%
Live - 5344 symbols - heartbeat 439s ago
· 2026-10-08 07:12
Pre-market
3.49
+1.16%
After-hours
3.46
+0.29%
Overnight
3.49
+1.16%
- Market cap
- 1.11B
- P/E (TTM)i
- -24.64
- P/Bi
- -16.51
- EPSi
- 0.02
- Div yieldi
- 0.00%
- 52W posi
- 29%
Reader sentiment
Are you bullish or bearish on MNKD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.7 percentage points.
Institutional ownership
- Held by institutions
- 57.55% -2.75pp
- Institutions
- 308 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund36.72%
Hedge Fund10.62%
VC/PE Fund3.93%
Public Company3.30%
Individual/Insider1.85%
Family Office/Trust1.61%
Private Company0.65%
Government Pension Fund0.48%
Insurance Company0.20%
Other40.64%
Top holders as of 2026-06-30
BlackRock
9.99% · 32.13M sh
Rubric Capital Management LP
5.60% · 18.00M sh
State Street Global Advisors
5.03% · 16.17M sh
Vanguard Capital Management, LLC
4.78% · 15.37M sh
Geode Capital Management, LLC
2.47% · 7.95M sh
Wellington Management Group
2.44% · 7.84M sh
Frazier Life Sciences Management, LP
2.05% · 6.60M sh
Deep Track Capital, LP
1.87% · 6.00M sh
180 Wealth Advisors, LLC
1.54% · 4.96M sh
FMR
1.28% · 4.10M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 29 buys · 21 sells
| Name | Role | Stake |
|---|---|---|
| Michael Castagna | Chief Executive Officer | 0.76% |
| Stuart Tross | Executive VP and Chief People & Workplace Officer | 0.27% |
| David Thomson | General Counsel | 0.19% |
| Steven Binder | Chief Financial Officer | 0.17% |
| Burkhard Blank | Executive VP of Research & Development and Chief Medical Officer | 0.08% |
| Sanjay Singh | Executive Vice President of Technical Operations | 0.08% |
| Anthony Hooper | Independent Director | 0.07% |
| Lauren Sabella | Chief Operating Officer | 0.04% |
| Ronald Consiglio | Independent Director | 0.04% |
| Jennifer Grancio | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-24 | Steven Binder | Chief Financial Officer | Automatic Disposition | -39,051 | $3.29 |
| 2026-09-09 | Steven Binder | Chief Financial Officer | Automatic Disposition | -33,558 | $3.81 |
| 2026-08-06 | Steven Binder | Chief Financial Officer | Automatic Disposition | -39,051 | $4.06 |
| 2026-07-16 | David Thomson | General Counsel | Automatic Disposition | -24,109 | $4.05 |
| 2026-07-16 | Steven Binder | Chief Financial Officer | Derivative Exercise and Sale | -76,880 | $4.06–4.09 |
| 2026-07-14 | David Thomson | General Counsel | Sale to Issuer | -4,636 | $4.09 |
| 2026-07-14 | David Thomson | General Counsel | Derivative Exercise and Sale | -93,790 | $4.09 |
| 2026-07-14 | Stuart Tross | Executive VP and Chief People & Workplace Officer | Derivative Exercise and Sale | -65,808 | $4.09 |
| 2026-07-14 | Stuart Tross | Executive VP and Chief People & Workplace Officer | Derivative Exercise and Retained | +27,982 | -- |
| 2026-07-14 | Michael Castagna | Chief Executive Officer | Sale to Issuer | -12,940 | $4.09 |
| 2026-07-14 | Michael Castagna | Chief Executive Officer | Derivative Exercise and Sale | -350,260 | $4.09 |
| 2026-07-14 | Steven Binder | Chief Financial Officer | Derivative Exercise and Retained | +16,910 | -- |
| 2026-07-14 | Christopher Prentiss | Chief Financial Officer | Sale to Issuer | -22,247 | $4.09 |
| 2026-07-14 | Dominic Marasco | President of Endocrine Business Unit | Sale to Issuer | -3,623 | $4.09 |
| 2026-07-14 | Sanjay Singh | Executive Vice President of Technical Operations | Derivative Exercise and Sale | -46,795 | $4.09 |
| 2026-07-14 | Sanjay Singh | Executive Vice President of Technical Operations | Derivative Exercise and Retained | +23,755 | -- |
| 2026-05-19 | Ronald Consiglio | Independent Director | Other Acquisition | +10,000 | $2.95 |
| 2026-05-19 | Ronald Consiglio | Independent Director | Other Derivative Acquisition | +99,337 | -- |
| 2026-05-19 | Christine Ann Mundkur | Independent Director | Other Derivative Acquisition | +82,781 | -- |
| 2026-05-19 | Michael Friedman | Independent Director | Other Derivative Acquisition | +82,781 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:12:30 · For reference only, not investment advice and not tailored to your situation.